<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376532</url>
  </required_header>
  <id_info>
    <org_study_id>TJU 06U.282</org_study_id>
    <nct_id>NCT00376532</nct_id>
  </id_info>
  <brief_title>Extracellular Matrix Marker of Arrhythmia Risk (EMMA)</brief_title>
  <acronym>EMMA</acronym>
  <official_title>Role of Matrix Metaloproteinase(MMP)9 and MMP 2 in Risk Stratification for Ventricular Tachycardia/Fibrillation in Patients With Implanted Cardioverter Defibrillator (ICD) Devices.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular
      tachycardia or fibrillation in patients who have implantable cardioverter defibrillator
      devices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sudden cardiac death (SCD) is responsible for 300,000-450,000 deaths per year in the United
      States. While it is well known that patients with both ischemic and non-ischemic
      cardiomyopathy (ICM, NICM) are at increased risk for SCD, there is little beyond ejection
      fraction which has proven useful as a noninvasive predictor to risk stratify these patients.

      Myocardial scar has been validated as an arrhythmic substrate in ischemic populations; the
      majority of successful ablations for lethal ventricular arrhythmias are performed on tissues
      in peri-infarct regions. Scar provides an anatomic electrical boundary where peri-infarct
      zones may lead to areas of slow conduction due to the disruption of inter-myocyte electrical
      conduction.

      Myocardial scar is a less organized collagen deposition which disrupts the typical cardiac
      extracellular matrix. The collagen matrix provides mechanical support to the myocardium
      dictating ventricular shape, size and stiffness. While typically relatively dormant, the
      fibrillar collagen matrix reflects a dynamic relationship between collagen synthesis mediated
      by fibroblasts and collagen degradation performed by matrix metalloproteinases (MMP).

      A marker for scar burden or a marker which could assess a patient's predilection to form scar
      after either an ischemic or non-ischemic insult may be useful in further risk stratifying
      this population. Since MMP levels may fluctuate in the course of ischemic or nonischemic
      injury a static promoter sequence which confers a higher level of MMP expression to an
      ischemic or nonischemic insult may prove to be a reliable marker. Functional polymorphisms of
      the MMP-9 gene promoters have been shown in multivariate analysis to be an independent
      predictor of cardiac mortality regardless of the mechanism of heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MMP-2</measure>
    <time_frame>At time of enrollment</time_frame>
    <description>Serum MMP-2 levels determined by Aushon Biosystems Searchlight® Protein Array Analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MMP-9</measure>
    <time_frame>At time of enrollment</time_frame>
    <description>Serum MMP-9 levels determined by Aushon Biosystems Searchlight® Protein Array Analysis.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">63</enrollment>
  <condition>Myocardiopathies</condition>
  <condition>Ischemia, Myocardial</condition>
  <condition>Arrythmia</condition>
  <condition>Death, Sudden, Cardiac</condition>
  <arm_group>
    <arm_group_label>ICD pacing or shock event</arm_group_label>
    <description>Subjects who experienced a device treatment, defined as a pacing event or a shock event</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No ICD pacing or shock event</arm_group_label>
    <description>Subjects who did not experience a treatment defined as a pacing event or a shock event</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients or outpatients with the cardiac device of interest implanted prior to
        enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LVEF of ≤ 35% measured within 6 months of ICD implantation

          -  NYHA class II-IV at the time of ICD implantation

          -  ICD implantation at least 1 year prior to enrollment

        Exclusion Criteria:

          -  Status post heart transplant

          -  Known malignancy in the past 2 years.

          -  Recent procedure, intervention or surgery within the past 90 days

          -  Acute MI, CABG, or PTCA/stent within the past 2 months.

          -  Active rheumatoid arthritis or pulmonary or hepatic fibrosis.

          -  Taking chronic steroid therapy for a medical condition

          -  Currently pregnant

          -  Enrolled in a concurrent study that may confound the results of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Whellan, MD MHS FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jefferson Heart Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2006</study_first_submitted>
  <study_first_submitted_qc>September 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2006</study_first_posted>
  <results_first_submitted>May 5, 2014</results_first_submitted>
  <results_first_submitted_qc>May 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2014</results_first_posted>
  <last_update_submitted>May 5, 2014</last_update_submitted>
  <last_update_submitted_qc>May 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Ischemia</keyword>
  <keyword>Cardiac Arrhythmia</keyword>
  <keyword>Defibrillator</keyword>
  <keyword>Matrix Metalloproteinase</keyword>
  <keyword>Genetic Polymorphism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects with Implanted Cardiac Defibrillators were enrolled from the Heart Institute Outpatient Clinic or from the inpatient Electrophysiology Lab at Thomas Jefferson University Hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ICD Event</title>
          <description>Subjects who experienced a device treatment, defined as a pacing event or a shock event</description>
        </group>
        <group group_id="P2">
          <title>No ICD Event</title>
          <description>Subjects who did not experience a treatment defined as a pacing event or a shock event</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31">Subjects with an event were enrolled beginning 09/14/2006.</participants>
                <participants group_id="P2" count="32">Subjects without an event were enrolled beginning 09/15/2006.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25">Last event subject enrolled 2/22/2008</participants>
                <participants group_id="P2" count="26">Last non-event subject enrolled 3/18/2008.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack sufficient blood sample</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population was determined by the enrolled subjects for whom the MMP2 and MMP9 assays were completed.</population>
      <group_list>
        <group group_id="B1">
          <title>ICD Pacing or Shock Event</title>
          <description>Subjects who experienced a device treatment, defined as a pacing event or a shock event</description>
        </group>
        <group group_id="B2">
          <title>No ICD Pacing or Shock Event</title>
          <description>Subjects who did not experience a treatment defined as a pacing event or a shock event</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MMP-2</title>
        <description>Serum MMP-2 levels determined by Aushon Biosystems Searchlight® Protein Array Analysis.</description>
        <time_frame>At time of enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ICD Pacing or Shock Event</title>
            <description>Subjects who experienced a device treatment, defined as a pacing event or a shock event</description>
          </group>
          <group group_id="O2">
            <title>No ICD Pacing or Shock Event</title>
            <description>Subjects who did not experience a treatment defined as a pacing event or a shock event</description>
          </group>
        </group_list>
        <measure>
          <title>MMP-2</title>
          <description>Serum MMP-2 levels determined by Aushon Biosystems Searchlight® Protein Array Analysis.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173493.4" spread="110996.7"/>
                    <measurement group_id="O2" value="139012.4" spread="68988.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MMP-9</title>
        <description>Serum MMP-9 levels determined by Aushon Biosystems Searchlight® Protein Array Analysis.</description>
        <time_frame>At time of enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ICD Pacing or Shock Event</title>
            <description>Subjects who experienced a device treatment, defined as a pacing event or a shock event</description>
          </group>
          <group group_id="O2">
            <title>No ICD Pacing or Shock Event</title>
            <description>Subjects who did not experience a treatment defined as a pacing event or a shock event</description>
          </group>
        </group_list>
        <measure>
          <title>MMP-9</title>
          <description>Serum MMP-9 levels determined by Aushon Biosystems Searchlight® Protein Array Analysis.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1033545.8" spread="1351216.4"/>
                    <measurement group_id="O2" value="680388.5" spread="992423.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ICD Pacing or Shock Event</title>
          <description>Subjects who experienced a device treatment, defined as a pacing event or a shock event</description>
        </group>
        <group group_id="E2">
          <title>No ICD Pacing or Shock Event</title>
          <description>Subjects who did not experience a treatment defined as a pacing event or a shock event</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David J. Whellan MD</name_or_title>
      <organization>Thomas Jefferson University</organization>
      <phone>215 955 2636</phone>
      <email>david.whellan@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

